ArticleThe Journal of clinical investigation2019

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Tori N Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.